Natera is finalizing its premarket approval application for an assay that predicts benefit from a drug developed by Roche, discussed in the context of the IMvigor011 trial.
2 reports, 2 independent
Updated Aug 19
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Natera is finalizing its premarket approval application for an assay that predicts benefit from a drug developed by Roche, discussed in the context of the IMvigor011 trial.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Hoffmann-La Roche
Swiss healthcare company
-
Natera
company in San Carlos, United States
Related events
- The FDA has delayed potential approval of a cancer treatment that utilizes Exelixis in combination with Roche's Tecentriq.
- The FDA approved various advanced therapies, including oral medication from Roche, a gene-targeting drug from Biogen, and a one-time gene therapy from Novartis.
- Nektar Therapeutics is seeking FDA review for its late-stage drug trials.
- The FDA recommended advancement for a new drug application submitted by a company.
- Emmaus Life Sciences is conducting Phase 3 trials for an Endari drug, preceding future FDA submission.
Coverage
Newest first; wire copies grouped- Clinical Trials ArenaNatera pursues ctDNA assay approval after Phase III victory Natera’s Signatera assay has been found to accurately predict if a patient with muscle-invasive bladder cancer (MIBC) will benefit from adj
- Business WireIMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit Topline results from the trial show that Signatera-positive patients trea